Orveon Global US Expands Columbus, Ohio, Corporate Operations
The company selected 343 North Front Street for its new office after a nationwide search. Orveon is expanding its footprint as it looks to attract top talent across a range of skill sets and backgrounds.
“As Orveon scales its operations in the U.S., we look forward to helping to grow the booming ecosystem of global companies in Columbus,” said Orveon CEO Pascal Houdayer. “We are seeking skilled talent and expertise with a passion for a new type of beauty with strong sustainability purpose, and we are confident we can find that team in Columbus as we build our new office.”
Orveon was formed after Boston-based private equity firm Advent International acquired the brands from Japanese cosmetics conglomerate Shiseido in December 2021. The company also has regional headquarters in London and Tokyo. Focused primarily on the prestige cosmetics and skincare categories, Orveon has exciting growth plans for its portfolio of brands and business.
“With locations in some of the world’s most impactful markets, including London and Tokyo, Orveon Global’s decision to open a new site in Columbus is evidence of Ohio’s competitiveness as a viable, international location in a covid-callibrated economy,” said JobsOhio President and CEO J.P. Nauseef. “This investment helps strengthen Orveon’s brands worldwide with talent from Ohio while bringing 150 new jobs to the Columbus Region.”
The Columbus Region economy boasts a highly-diversified base of companies, with no industry accounting for more than 18% of employment.
The Evolution of the Megasite
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Rail Gains Advantage Amidst Supply Chain Snarls
The 2021 Top States for Doing Business Reflect Their Locational Advantages
18th Annual Consultants Survey: Access to Major Markets and Skilled Labor Are Clients’ Primary Concerns
2021 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Innovative and Collaborative Design Sets the Stage for Life Science Innovation